Gilead Wins EU Approval for High-priced Hep C Drug

Source: Gilead

Nov 18, 2014

Gilead Sciences has been granted marketing authorization by the European Commission for its next-generation hepatitis C drug, opening the door for the drug to be sold in 28 countries.

The drug, Harvoni, is the first once-daily tablet targeting chronic hepatitis C. It was approved last month by the U.S. FDA and priced at a staggering $95,000. European pricing has yet to be determined and must be negotiated with individual countries.

Harvoni combines the drug ledipasvir with Sovaldi, Gilead's first-generation hepatitis C drug, which was approved in the U.S. in December 2013 and in Europe in January 2014.

Read the Gilead press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments